Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]
Top Cited Papers
- 1 March 2013
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 111 (10), 1394-1400
- https://doi.org/10.1016/j.amjcard.2013.01.287
Abstract
No abstract availableKeywords
Funding Information
- Virginia Commonwealth University (KL2RR031989, AI-15614)
- American Heart Association (KL2RR031989, AI-15614)
- National Institutes of Health (KL2RR031989, AI-15614)
This publication has 41 references indexed in Scilit:
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Regulation of the Inflammatory Response in Cardiac RepairCirculation Research, 2012
- The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouseProceedings of the National Academy of Sciences of the United States of America, 2011
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesBlood, 2011
- The role of IL-1 in the pathogenesis of heart diseaseArchivum Immunologiae et Therapiae Experimentalis, 2009
- Immunological and Inflammatory Functions of the Interleukin-1 FamilyAnnual Review of Immunology, 2009
- Long-Term Trends in the Incidence of Heart Failure After Myocardial InfarctionCirculation, 2008
- Interleukin-1 Receptor Type I Signaling Critically Regulates Infarct Healing and Cardiac RemodelingThe American Journal of Pathology, 2008
- The immune system and cardiac repairPharmacological Research, 2008
- Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)Trials, 2008